Professional Documents
Culture Documents
To,
Dr. Md. Hasanath Ali
Associate Professor
Institute of Business Administration
University of Rajshahi
Rajshahi.
Dear Sir,
Within the time limit and my knowledge & capability, I paid sincere efforts to
study related materials, documents, observed operations performed in Square
Pharmaceuticals Ltd and examine relevant records for preparation of the
report. But there may exist some mistakes and errors due to various
limitations. Therefore, I beg your kindness in advance.
Ill be available anytime if you confront any difficulty to translate any aspect of
this report.
You are requested to accept this internship report and oblige me thereby.
Sincerely yours
Associate Professor
Institute of Business Administration
University of Rajshahi
Rajshahi.
RECOGNITION LETTER
I am very pleased to certify that Saumitra Kumar Paul bearing roll no. 060007
a student of MBA program, Institute of Business Administration, University of
Rajshahi was engaged in Square Pharmaceuticals Ltd. for the period from
10th November 2008 to 10th February 2009 to conduct the internship program.
He completed the assigned task successfully.
During the period of his internship, I found him sincere, punctual, creative,
hard working and dedicated in doing his assigned jobs.
Senior Manager
Market Research and Planning Cell
Square Pharmaceuticals Ltd.
Dhaka.
ACKNOWLEDGEMENT
I owe a debt of gratitude to all those people without whom this report would
have never been accomplished. These people, not only mentored me but they
also made it a point that this study becomes a classy piece of study and its
only their patronage, their mentoring, their constructive assistance and
guidance that has made the study really meaningful and a well thought out
piece of literature.
It would be true to say that, without the helping hand of Mr. Md.
Kamruzzaman Khan, Executive, and Mr. H. M. Ashiquer Rahman,
Executive, the whole project might have been unsuccessful. These two
Officers are entitled to receive thanks for their patience and assistance.
Ill remember such an obliging personality like Mr. Monsur Rahman Khan,
Executive, MRPC. He always behaved with me affectionately & cordially.
My sincere acknowledgement also goes to Mr. Mark Rupayan. His
tremendous support always followed me as my own shadow does.
At the last, but not the least, A special recognition goes to Mr, Nasir Uddin
Ahmed who provided sincere cooperation to manage my internship in
Square Pharmaceuticals Ltd and on demand information necessary to
prepare this report.
Where this report succeeds I share the credit, where it errs I alone accept the
responsibility.
Of late, the issue of market expansion has attracted the significant attention of
academia as well as industry. Market expansion as a strategic growth option
is particularly relevant in developing countries like Bangladesh because of
very low product penetration and consumption levels.
Letter of Transmittal i
Acceptance Letter ii
Recognition Letter iii
Acknowledgement iv
Executive summery v
1 Chapter 1: Introduction 1
1.1 Origin of the report 2
1.2 Rationality of the study 2
1.3 Scope of the study 2
1.4 Objective of the study 3
1.5 Methodology 3
1.6 Collection of the data 3
1.7 Limitations of the study 3
1.8 List Of Abbreviations Used 4
1.9 Definition of the terms 5
5 Chapter 5: Recommendations 36
6 Chapter 6: Conclusion 41
Bibliography 42
Appendix 43
Part 1
Introduction
1
Introduction
Besides this, Of late the issue of market expansion has attracted the
significant attention of academia as well as industry. Market expansion as a
strategic growth option is particularly relevant in developing countries like
Bangladesh because of very low product penetration and consumption levels.
Therefore, this study is very much significant in terms of modern business
environment.
2 | Page
only. In-depth data were not always available on-demand due to some
unavailable reasons. SWOT analysis of the company has been done. Some
recommendations also have been worked out to improve the current
situations for the company.
1.5 Methodology
Information used to prepare this report has been collected from both the
primary and secondary sources which together provided a more
comprehensive information.
The secondary data was accumulated from two sources- a. internal and
b. external. The former sources were annual reports, periodicals, articles and
brochures published by the company. But in the later case, journals, research
papers and articles from various online sources.
3 | Page
1.7 Limitations Of The Study
The most important of them was time constraint. Time was not adequate
to complete the study more perfectly.
4 | Page
1.9 Definition Of The Terms
Value Proposition. Chesbrough and Rosenbloom (2002) define the
value proposition as the value created for users by the offering based on
the technology.
5 | Page
Chapter 2
An Overview of
Square Pharmaceuticals Ltd.
6 | Page
2
Company Overview
2.0 INTRODUCTION
SQUARE Pharmaceuticals Limited (SPL) is the largest pharmaceutical
company in Bangladesh and is leading the Pharmaceuticals sector from the
very beginning. It has been continuously in the 1 stposition among all national
and multinational companies since 1985. It was established in 1958 and
converted into a public limited company in 1991. The sales turnover of SPL
was more than Taka 7.5 Billion (US$ 107.91 million) with about 16.92%
market share (April 2006 March 2007) having a growth rate of about 23.17%.
SQUARE today symbolizes a name - a state of mind. But its journey to the
growth and prosperity has been no bed of roses. From the inception in 1958,
it has today burgeoned into one of the top line conglomerates in Bangladesh.
Square Pharmaceuticals Ltd., the flagship company, is holding the strong
leadership position in the pharmaceutical industry of Bangladesh since 1985
and is now on its way to becoming a high performance global player.
7 | Page
2.1 CORPORATE HISTORY
Square Pharmaceuticals started as a Partnership Firm in 1958. It converted
into a Private Limited Company in 1964. The company made its initial price
offering in 1995. It has achieved MHRA certificate as the first pharmaceutical
company of Bangladesh.
8 | Page
2.2 VISION
Square views business as a means to the material and social wellbeing of the
investors, employees and the society at large, leading to accretion of wealth
through financial and moral gains as a part of the process of the human
civilization.
2.3 MISSION
Its Mission is to produce and provide quality & innovative healthcare relief for
people, maintain stringently ethical standard in business operation also
ensuring benefit to the shareholders, stakeholders and the society at large.
2.4 OBJECTIVE
Its objectives are to conduct transparent business operation based on market
mechanism within the legal & social frame work with aims to attain the
mission reflected by its vision.
Make sure that they are not complicit in human rights abuses.
9 | Page
Businesses should uphold the freedom of association and the effective
recognition of the right to collective bargaining;
The elimination of all forms of forced and compulsory labor;
Square strives, above all, for top quality health care products at the
least cost reaching the lowest rungs of the economic class of people in
the country. Square values our social obligations.
Square owes our shareholders and strive for protection of their capital
as well as ensure highest return and growth of their assets.
Square strives for best compensation to all the employees who
constitute the back-bone of the management and operational strength
of the company through a pay-package composing salary/wages,
allowances, bonuses, profit participation, leave salary and
superannuation & retirement benefits.
Square strives for the best co-operation of the creditors & debtors the
banks & financial Institutions who provide financial support when
Square needs them, the suppliers of raw materials & suppliers who
offer them at the best prices at the opportune moments, the
providers of utilities-power, gas & water etc. and the customers who
buy our products & services by redeeming their claim in time by making
prompt payment and by distributing proper product on due dates to our
customers.
10 | Page
for the human civilization.
activities covering inter alia not being limited to, disclosure & reporting
Director Director
to shareholders, holding(Account
AGM &infinance)
time, distribution of dividends (Marketing & Sales)
and other benefits to shareholders, reporting/dissemination of
GM GM (HR) GM GM
(Supply price sensitive information, acquisition of shares by(marketing)
insiders, (sales)
Chain)
recruitment & promotion of staff, procurement & supplies, sale of
DGM DGM DGM DGM
assets etc. all that directly and indirectly(IMD)
affect the interest
(PMD) of
concerned groups - the shareholders, the creditors, suppliers,
AGM AGM AGM AGM AGM AGM
employees, government and the public in general. Depo
Square strives for equality between sexs, races, religions and regions NSM
Executive Executive Executive Executive Executive Executive Executive Executive Executive SMPO
MPO
11 | Page
Source: Primary interview with HR executive of SPL
The organisms through which the corporate governance functions are carried
out are:
Board Of Directors :
13 | Page
conditions of the Articles of Association and the provisions of the
Companies Act 1994 are not fulfilled.
b) Role & Responsibilities. The main role of the Board of Directors,
which is the highest level of authority, is to provide general
superintendence, oversee the operations and control the affairs of
the company through appropriate delegation and accountability
processes via the lines of command. However the Board of Directors
hold the ultimate responsibility & accountability with due delligence
for conducting the activities of the company as per provisions of law in
the interest of the shareholders, the stakeholders, the state and the
society. The Board of Directors, in fulfillment of its responsibility hold
periodic meetings, at least once a quarter and provide appropriate
decisions/directions to the Executive Management. Such meetings
usually consider operational performance, financial results, review of
budgets, capital expenditure proposals for BMRE or new
projects/divisions/product lines, procurement of funds by issue of
shares or borrowing, procurement of raw materials, plant & machinery,
pricing of products/discounts, recruitment, training and promotion of
officers, approval of audited accounts and distribution of dividends and
other interest of the stakeholders including the employees and workers.
The Board of Directors take special care in designing and articulating
productivity and compensation plans of employees and workers and
rewarding them appropriately on the basis of quality and quantity of
performance as an incentive. Board also remains responsible for
removal of operational hazards to life and health of workers, friendly
environmental work condition and social relationship as demanded of good
citizen in a country.
14 | Page
responsible to the public for publication of any price sensitive
information as per SEC regulation. A qualified Chartered Secretary
is in charge for all these responsibilities as Company Secretary.
15 | Page
2.9 THE EXECUTIVE MANAGEMENT
The Executive Management is led by the Managing Director (CEO) who
is appointed by the Board of Directors for a term of 5 years
(renewable) with the approval of shareholders in the Annual General
Meeting. The Managing Director is supported by professional, well
educated, trained and experienced team consisting of Executive Directors,
Directors, General Managers and a host of Senior Executives in the hierarchy
of management. The Board has approved an organogram with modern
features ensuring clear lines of delegation of authority and reporting for
accountability for effective decision making evaluation of performance on
merit for both rewarding and disciplinary action. The Executive
Management is responsible for preparation of budgetary segment plans/sub-
segment plans for every cost/profit centers and are held accountable for
performance therefore. The Executive Management is aided by
committee(s)/sub-committee(s) in carrying out its functions.
16 | Page
dividend payouts tomorrow without regard for the sacrifices we make today
to allow their greater consumption tomorrow.
The Company holds regularly as per law the Annual General Meeting
with adequate notice and disclosures in the Directors' Report and the
Auditors' Report on Accounts/Notes and resolutions are passed with
consensus and unanimity. All reasonable and practicable suggestions are
17 | Page
implemented with good grace. Special Resolutions are passed in General
Meeting with due notices.
18 | Page
2.14 PRESENT FINANCIAL POSITION
Capital Resources Table: 2.1
ASSETS
31-03-08 31-03-07
19 | Page
6,199,135 5,482,088
995,648 867,088 760,536
6,089,905 5,332,047 4,721,552
2,564,503 2,172,593 1,906,592
1,533,043 1,513,019 1,151,636
1,165,865 1,255,848 970,044
6,402,015 5,568,790 4,590,142
9,298,987 7,907,933 6,021,497
2,334,925 1,902,331 988,611
4,031,685 3,242,502 2,016,056
2,260,755 1,949,949 1,250,676
1.66 1.61
4,320,000 3,600,000
77 70
15% 20%
623 513
627.92 485.02
140.44 108.48
146.64 112.70
3,768 2,272
3,766 2,316
26.83 20.94
10,486 9,270
949 895
796 740 686
764 705 661
Sources: Annual report 2008, SPL
2.15 HUMAN RESOURCES
2007-08 2006-07 2005-06 2004-05 2003-04
It has a team of more than 300 well-trained employees to market its product
countrywide which is second to none.
Square strives for best compensation to all the employees who constitute the
back-bone of the management and operational strength of the company
through a pay-package composing salary/wages, allowances, bonuses,
profit participation, leave salary and superannuation & retirement benefits.
20 | Page
2.16 TECHNOLOGICAL UPGRADATION
The company is endeavoring to upgrade and adopt new technology in
production, quality control, distribution and administration of its products
to patients. During the year (2007-2008) the company invested an
amount of Tk. 36,424,234 in improving its Laboratory.
21 | Page
country. Those are situated at Dhaka, Pabna, Bogra, Rangpur, Khulna,
Barisal, Comilla, Mymensingh, Chittagong, Noakhali, Sylhet, Tangail,
Rajshahi, Faridpur and Naryanganj. It uses own transport system to deliver its
product to the stockist and retailer.
b. Pabna Unit
Pabna Unit is the first manufacturing facility of SQUARE Pharmaceuticals
Ltd. and started operation in 1958. It is a modern plant that fully complies with
WHO cGMP Requirements. It has earned ISO 9001 Certificate in 1998, for
which Auditor was Orion Registrar Inc., USA. Again, its Quality Management
System upgraded to 2000 version in 2002.
c. Pesticide unit
Pesticide Unit is a newly formed unit dedicated to the diversification of agro
business through agricultural chemicals and public health insecticides. The
main operations include repacking, selling and marketing of insecticides,
fungicides, and herbicides of Chimac-Agriphar s.a., Belgium and FMC
Corporation, USA.
d. Cephalosporins Unit
Dedicated and state-of-the-art Cephalosporins Manufacturing Facility is built
as per the requirement of International GMP standard like EMEA, UK MHRA
22 | Page
and US FDA. This world class facility manufactures Cephalosporin antibiotics
in Tablets, Capsules, Dry Syrup and Injectable preparations.
23 | Page
2.22 PRESENT MARKET POSITION
Fig: 2.1
20
Square
18
16
14
12
10
8
4 Beximco
e
ar 2
et sh
0 Incepta
rk
a
m
Acme
Drug Int.
Sanofi-Aventis
Renata
Eskayef
Aristopharma ACI
0 1 2 3 4 5 6 7 8 9 10 11
Market standing
24 | Page
2.23 EXPORT
The company is continuously pressing hard for expanding it's export
sales. During the year under review, the exports amounted to Tk. 212.49
million as against Tk. 192.95 million in previous year, a 10.13%
increase. The exports are expected to rise in the forthcoming years so far.
As the Company has secured license under UK MHRA, it is expected
that the export potential will increase substantially in the near future. It
may be mentioned that the company has, for the first time, exported basic
chemicals for over Tk. 2 million during the year. The company is making
entry into foreign markets and making efforts in registering its products in
USA/EU countries for which is has already set up a modern state-of-art
production facilities at Kaliakoir, Gazipur. The company has already
secured permission for marketing its products in UK/EU countries.
SPL
Fig: 2.2
25 | Page
2.26 REVENUE MODEL
Total revenues are highly dependant on sales from a small number of drugs.
Because, In the pharmaceutical industry, the pharmaceuticals products are
divide in to two broad categories: (a) OTC- Can be advertised of
commercialized (b). POM- Strictly regulated in terms of pricing and
approaches. SPL strives to increase the sale of those POM drugs.
26 | Page
Chapter 3
27 | Page
3
Market Expansion Strategy of SPL
Product Price
Target
customers
(doctors &
physicians)
Promotion Place
(personal selling
through (domestic &
relationship) foreign)
Fig: 3.1
b) Target Customers.. Rather than the consumer of the medicine, the key
customers for SPL has been the physician. Physicians are considered here as
opinion leader. The major innovative drugs can not be purchased without a
prescription provided by a doctor. SPLs main selling task has been directed,
therefore, not at the user, but at physicians.
28 | Page
Doctors and physicians are segmented on the basis of its therapeutic drug
segment. As for example, NASAL DROPS products are communicated at
E.N.T specialists. Therefore, if SPL has NASAL DROPS product line, then
E.N.T. specialists are treated its target customers. Besides this, general
physicians are also its target customers.
c) Value Proposition.. SPL has presently been offering its products to its
market segment with the value proposition Utmost quality, Excellent efficacy.
The product list according to generic segment can be found in appendix part.
As per the NDA 2005, regulatory authority pursuing Rational pricing of drugs
to ensure essential drugs available to the end-users at affordable prices. On
the basis of that policy, SPL has been pursuing two different kinds of pricing
policy-
a. For OTC product, all most similar price as the competitors.
b. For POM product, competitive pricing.
29 | Page
There are also few exceptions. If SPL introduces a product first in the market,
it charges little bit higher price than its competitors, but within the rules and
regulations of Drug Administration.
f) Place.. SPL has the strongest domestic distribution network for smoothing
distribution of medicines to all parts of the country. Currently it has 15 depots
all over the country. Those are situated at Dhaka, Pabna, Bogra, Rangpur,
Khulna, Barisal, Comilla, Mymensingh, Chittagong, Noakhali, Sylhet, Tangail,
Rajshahi, Faridpur and Naryanganj. It uses own transport system to deliver its
product to the stockist and retailer.
30 | Page
promotional materials. If a new drug is to be more expensive, then it needs
to demonstrate that its superior performance is worth it.
Non-core customer
(retailer)
Customer
(C&F)
3.3 EXPORT
This is an important market expansion strategy of SPL. Because the past fifty
years have seen a dramatic lowering of barriers to cross-border trade and
investment, For example, the average tariff rate on manufactured goods
traded between advanced nations has fallen from around 40 percent to under
4 percent. Similarly, in nation after nation, regulations prohibiting foreign
companies from entering domestic markets and establishing production
facilities, or acquiring domestic companies, have been removed.
31 | Page
3.4 LOW MANUFACTURING COST THROUGH VERTICAL INTEGRATION
To expand its market with low cost products, SPLs strategy is to integrate
itself more vertically so that it can get the raw materials cheaply. It has its own
API manufacturing facilities and more API factory is being established.
Products
Present New
ten Product
Market
sPre penetration development
s
Market
w Market Diversification
Ne development
Fig: 3.3
32 | Page
Chapter 4
33 | Page
4
Marketing Problems of SPL
2. I didnt find SPL adopting any strategy to create brand loyalty. But
client is more profitable than customer in terms of both transaction as
well as positive word-of-mouth communication. He himself can be an
opinion leader.
3. Holding the heaviest product portfolio should not be the ultimate goal at
all. Emphasis must be given on how early a new product can be
launched in the market place than the competitor.
4. At present, SPL gets only 20% raw materials from its API plant and the
rest are to be imported. It increases product cost.
34 | Page
Chapter 5
Recommendations
35 | Page
5
Recommendations
Customer
(stockist)
Profit
Marketing & Sales Non-core customer
Team sharing (retailer)
Core customer
(doctor)
Fig: 5.1
End customer
(patient)
In this model, Retailers have been selected as new opinion leader, besides
the doctors & physicians. In return, they will enjoy above average profit
margin by selling SQUARE product.
36 | Page
5.2 CUSTOMER ONCE, CLIENT FOR EVER
Client is more profitable than customer in terms of both transaction as well as
positive word-of-mouth communication. He himself can be an opinion leader.
So, I am suggesting to adopt some programs that will let its customers be
transformed into clients. The following model would better describe this
concept: Customer
(stockist)
Core customer
(doctor)
Fig: 5.2
I am citing some instances here which may be useful for this strategy:
a. Mobile Hospital service with free treatment and medicine.
b. Health awareness program in rural area.
c. Modernization of educational institute or public hospital etc.
37 | Page
5.4 WHAT I HAVE TODAY, OTHER WILL HAVE TOMORROW
SPL is always striving to maintain the highest product portfolio among the
competitors for its product development strategy. Holding the heaviest product
folio should not be the ultimate goal at all. Emphasis must be given on how
early a new product can be launched in the market place than the competitor.
SPL
Fig: 5.3
38 | Page
5.8 ACT LOCALLY, THINK GLOBALLY
As the Company has secured license under UK MHRA, it has created a
tremendous opportunity for SPL to expand globally. Not only that, in nation
after nation, regulations prohibiting foreign companies from entering domestic
markets and establishing production facilities, or acquiring domestic
companies, have been removed. As a result of these two developments, there
has been a surge in both the volume of international trade and the value of
foreign direct investment. Between 1950 and 2000, the volume of world trade
increased more than twenty-fold. So, SPL must grab this opportunity.
39 | Page
Chapter 6
Conclusion
40 | Page
6
Conclusion
The purpose of this paper has been to analyze the market expansion activities
of Square Pharmaceuticals Ltd. SPL is a very big business organization.
Therefore, its very difficult on my part to analyze its each and every strategy
precisely in this small study.
But finally I can say this much that it has a large potential both in the short and
long run due to its sound distinctive competencies .
41 | Page
Bibliography
th
Philip Kotler & Gary Armstrong, 10Edition, Principles of Marketing,
Pearson Education International, New Jersey, USA.
Annual Reports of Square Pharmaceuticals Ltd.
www.squarepharma.com.bd
42 | Page
Appendix
43 | Page
44 Lebac 1 gm IV Injection Cephradine 1 gm
45 Lebac 500 mg Injection Cephradine 500 mg
46 Lebac 250 Capusle Cephradine 250 mg
47 Lebac 500 Capsule Cephradine 500 mg
48 Lebac Dry Syrup Cephradine 125 mg / 5 ml
49 Lebac Pediatric Drops Cephradine 125 mg / 1.25 ml
50 Lebac Forte Suspension Cephradine 250 mg / 5 ml
51 Loracef 500 Capusle Cefaclor 500 mg
52 Loracef Suspension Cefaclor 125 mg / 5 ml
53 Loracef Pediatric Drops Cefaclor 125 mg / 1.25 ml
54 Loracef 375 ER Tablets Cefaclor 375 mg
55 Maxcef 250 mg Injection Cefotaxime 250 mg
56 Maxcef 500 mg Injection Cefotaxime 500 mg
57 Maxcef 1 gm Injection Cefotaxime 1 gm
58 Mexlo 400 Tablet Lomefloxacin 400 mg
59 Moxacil 250 Capsule Amoxycillin Trihydrate 250 mg
60 Moxacil 500 Injection Amoxycillin 500 mg / vial
61 Moxacil 500 Capsule Amoxycillin Trihydrate 500 mg
62 Moxacil Dry Syrup Amoxycillin 125 mg / 5 ml
63 Moxacil Forte Suspension Amoxycillin 250 mg / 5 ml
64 Moxacil DT Amoxycillin 250 mg
65 Moxacil Pediareic Drops Amoxycillin 125 mg / 1.25 ml
66 Moxacil 875 Tablet Amoxycillin Trihydrate 875 mg
67 Moxaclav 375 Tablet Amoxycillin + Clavulanic acid 250 mg + 125 mg
68 Moxaclav 625 Tablet Amoxycillin + Clavulanic acid 500 mg + 125 mg
69 Moxaclav Dry Syrup Amoxycillin + Clavulanic acid (125 + 31.25) mg / 5 ml
70 Moxaclav Dry Syrup Amoxycillin + Clavulanic acid (125 + 31.25) mg / 5 ml
71 Moxaclav Forte Suspension Amoxycillin + Clavulanic acid (400 + 57.50) mg / 5 ml
72 Moxaclav 1 gm Tablet Amoxycillin + Clavulanic acid 875 mg+ 125 mg
73 Nalid 500 Tablet Nalidixic Acid 500 mg
74 Nalid Dry Syrup Nalidixic Acid 300 mg / 5 ml
75 Penvik Dry Syrup Phenoxymethyl Penicillin 125 mg / 5 ml
76 Penvik 250 Tablet Phenoxymethyl Penicillin 250 mg
77 Penvik DS Tablet Phenoxymethyl Penicillin 500 mg
78 Penvik Forte Dry Syrup Phenoxymethyl Penicillin 250 mg / 5 ml
79 Phylopen 250 Capsule Flucloxacillin 250 mg
80 Phylopen Dry Syrup Flucloxacillin 125 mg / 5 ml
81 Phylopen Forte Dry Syrup Flucloxacillin 250 mg / 5 ml
82 Phylopen DS Capsule Flucloxacillin 500 mg
83 Phylopen 500 Injection Flucloxacillin 500 mg / vial
84 Remac 500 Tablet Clarithromycin 500 mg
85 Rutix 200 Tablet Ofloxacin 200 mg
86 Rutix 400 Tablet Ofloxacin 400 mg
87 Saga 200 mg Tablet Sparfloxacin 200 mg
88 Specbac 1 gm IV Injection Meropenem 1 gm
89 Specbac 500 mg IV Injection Meropenem 500 mg
90 Tazid 250 mg IM/IV Injection Ceftazidime 250 mg
91 Tazid 500 mg IM/IV Injection Ceftazidime 500 mg
92 Tazid 1 gm IM/IV Injection Ceftazidime 1 gm
93 Tetrax 500 Capsule Tetracycline HCl 500 mg
94 Trevox 500 Tablet Levofloxacin 500 mg
95 Trevox 750 Tablet Levofloxacin 750 mg
44 | Page
96 Trevox Syrup Levofloxacin 125 mg / 5 ml
97 Vanprox 100 Capsule Cefpodoxime Proxetile 100 mg
98 Vanprox 200 Capsule Cefpodoxime Proxetile 200 mg
99 Vanprox Pediatric Drops Cefpodoxime Proxetile 20 mg / ml
100 Vanprox Dry Syrup Cefpodoxime Proxetile 40 mg / 5 ml
101 Vanprox Forte Suspension Cefpodoxime Proxetile USP 80 mg/5ml
102 Zimax 500 Tablet Azithromycin 500 mg
103 Zimax 250 Capsule Azithromycin 250 mg
104 Zimax Suspension Azithromycin 200 mg / 5 ml
105 Zimax Suspension Azithromycin 200 mg / 5 ml
45 | Page
40 Miclofenac 50 Tablet Diclofenac Sodium + Misoprostol 50 mg + 200 mcg
41 Miclofenac 75 Tablet Diclofenac Sodium + Misoprostol 75 mg + 200 mcg
42 Norvis Tablet Tiemonium Methylsulphate 50 mg
43 Norvis Injection Tiemonium Methylsulphate 5 mg / 2 ml
44 Panodin SR Tablet Etodolac USP 600 mg
45 Penrif 15 Cream Methylsalicylate + Menthol 15% + 10%
46 Penrif 30 Cream Methylsalicylate + Menthol 30% + 8%
47 Selecox 100 tablet Celecoxib 100 mg
48 Selecox 200 tablet Celecoxib 200 mg
49 Sonap 10% Gel Naproxen 10%
50 Sonap 250 tablet Naproxen 250 mg
51 Sonap 500 tablet Naproxen 500 mg
52 Sonap 500 Suppository Naproxen 500 mg
53 Tilex 500 Tablet Glucosamine HCl 500 mg
54 Torax 10 Tablet Ketorolac Tromethamine 10 mg
55 Torax 10 Injection Ketorolac Tromethamine 10 mg/ml
56 Torax 30 Injection Ketorolac Tromethamine 30 mg/ml
57 Torax 60 Injection Ketorolac Tromethamine 60 mg/ml
58 Tory 60 Tablet Etoricoxib 60 mg
59 Tory 90 Tablet Etoricoxib 90 mg
60 Tory 120 Tablet Etoricoxib 120 mg
61 Xflam 200 tablet Dex-Ibuprofen INN 200 mg
62 Xflam 300 tablet Dex-Ibuprofen INN 300 mg
63 Xflam 400 tablet Dex-Ibuprofen INN 400 mg
64 Xripa tablet Nefopam HCl INN 30 mg
65 Xripa Injection Nefopam HCl INN 20 mg/ml
66 Xtra 10 tablet Valdecoxib 10 mg
67 Xtra 20 tablet Valdecoxib 20 mg
67 Timotor tablet Trimebutine Maleate INN 100 mg
46 | Page
9 Fexo 120 tablet Fexofenadine HCl 120 mg
10 Fexo 180 tablet Fexofenadine HCl 180 mg
11 Loratin tablet Loratadine 10 mg
Loratadine+Pseudoephedrine
12 Loratin Plus Tablet 10 mg+ 240 mg
sulphate
13 Loratin suspension Loratadine 5 mg/5ml
14 Loratin FT Loratadine 10 mg
15 Sedno tablet Desloratadine 5 mg
16 Sedno syrup Desloratadine 2.50 mg / 5 ml
47 | Page
37 Esmo LA capsule Isosorbide Mononitrate 50 mg
38 Freflo Tablet Frusemide + Spironolactone 20 mg + 50 mg
39 Esordin Tablet Isosorbide Dinitrate 10 mg
40 Fusid injection Frusemide 20mg/amp
41 Fusid tablet Frusemide 40mg
42 Fusid 40 Plus Tablet Frusemide + Spironolactone 40mg + 50 mg
43 Nidipine tablet Nifedipine 10mg
44 Nidipine SR tablet Nifedipine 20mg
45 Nimocal Tablet Nimodipine 30 mg
46 Oxyfyl CR Tablet Pentoxifylline 400 mg
47 Levocar Solution Levocarnitine 500 mg / 5 ml
48 Levocar Tablet Levocarnitine 330 mg
49 Lipired 200 Capsule Fenofibrate 200 mg
50 Osiden Injection Adenosine 6 mg/2ml
1.5 mg Sustained
51 Repres 1.5 SR Tablet Indapamide
Release
52 Repres Plus 2 tablet Indapamide + Perindopril 0.625 mg + 2 mg
53 Repres Plus 4 tablet Indapamide + Perindopril 1.25 mg + 4 mg
54 Ripril 1.25 Capsule Ramipril 1.25 mg
55 Ripril 2.5 Capsule Ramipril 2.5 mg
56 Ripril 5 Capsule Ramipril 5 mg
57 Ripril 10 Capsule Ramipril 10 mg
58 Ripril 1.25 Tablet Ramipril 1.25 mg
59 Ripril 2.5 Tablet Ramipril 2.5 mg
60 Ripril 5 Tablet Ramipril 5 mg
61 Ripril plus 2.5/12.5 tablet Ramipril BP + Hydrochlorthiazide BP 2.5 mg + 12.5 mg
62 Ripril plus 5/25 tablet Ramipril BP + Hydrochlorthiazide BP 5 mg + 25 mg
63 Rosuva 10 Tablet Rosuvastatin 10 mg
64 Simacor 10 Tablet Simvastatin 10 mg
65 Vasopril 5 tablet Enalapril Maleate 5mg
66 Vasopril 10 tablet Enalapril Maleate 10mg
48 | Page
10 Secnid 500 Suspension Secnidazole 500 mg
11 Secnid DS Tablet Secnidazole 1 gm
(2000
Vit.A+Vit.D+Vit.B1+Vit.B2+Vit.B6+Vit. IU+200IU+0.70mg+0.85
23 Filwel Kids Syrup
C+Vit.E+Nicotinamide+Cod liver oil mg+0.35mg+17.5mg+1.
5mg+9 mg+0.1gm)/5ml
49 | Page
31 Zesup Syrup Zinc Sulphate 10 mg Zn / 5 ml
32 Zesup Forte Syrup Zinc Sulphate 20 mg Zn / 5 ml
33 Z-DT 10 Zinc Sulphate 10 mg
34 Z-DT 20 Zinc Sulphate 20 mg
50 | Page
3 Kensten-VT (Vaginal Tablet) Clotrimazole 100 mg
4 Betameson-N Top. Cream Betamethasone+ Neomycin (1mg+5mg)/gm
5 Dermasol Cream Clobetasol Propionate 0.05%
Clobetasol Propionate + Neomycin (0.5 mg+5 mg+1 lac
6 Dermnasol-N Cream
Sulphate + Nystatin unit)/gm
7 Dermasol Ointment Clobetasol Propionate 0.05%
Clobetasol Propionate + Neomycin (0.5 mg+5 mg+1 lac
8 Dermasol-N Ointment
Sulphate + Nystatin unit)/gm
9 Diprobet Cream Betamethasone Dipropionate BP 0.5mg/gm
10 Diprobet Ointment Betamethasone Dipropionate BP 0.5mg/gm
11 Equra Cream Urea 10.00%
12 Eromycin 3 % Lotion Erythromycin 3%
13 Ezex 0.05% Cream Clobetasone Butyrate 0.05%
14 Ezex 0.05% Ointment Clobetasone Butyrate 0.05%
15 Fona Cream Adapalene 0.10%
16 Fungidal HC Cream Miconazole nitrate+ Hydrocortisone (20mg+10mg)/g
17 Fungidal Cream Miconazole nitrate 20mg/gm
Econazole Nitrate +Triamcenolone
18 Pevitin Cream 1% + 0.1%
Acetonide
19 Genacyn Topical Ointment Gentamicin 1mg/gm
20 Gelora Gel Miconazole 2% (W/W)
21 Nebanol Ointment Neomycin Sulphate + Bacitracin 5mg+9.16mg/g
22 Nebanol Powder Neomycin sulphate+Bacitracin (5mg+4.56mg)/g
Neomycin sulphate+Bacitracin + 3.5 mg + 400 IU + 5000
23 Nebanol Plus Ointment
Polymixin IU
24 Nilac Gel Tretinoin 0.03%
25 Oni Cream Betamethasone DP+Clotrimazole 0.05%+1%
26 Pracort Ointment Hydrocortisone Acetate + Pramoxine 1% + 2.5%
27 Pracort Cream Hydrocortisone Acetate + Pramoxine 1% + 2.5%
28 Remus cream Tacrolimus 0.01%
29 Scabex Cream Permethrin 5%
30 Scabex Cream Permethrin 5%
31 Ticas 0.005% Ointment Fluticasone Propionate 0.005%
32 Ticas 0.05% Cream Fluticasone Propionate 0.05%
33 Topicort Cream Hydrocortisone Acetate 1.00%
34 Xfin Cream Terbinafine 1.00%
35 Bactrocin 2% Ointment Mupirocin 2.00%
51 | Page
Guaiphenesin + Pseudoephedrine + (100mg + 30mg +
8 Tusca Syrup
Triprolidine HCl 1.25mg)/5ml
9 Nectar Linctus Glycerol BP+Liquid Sugar ph.grd (0.75ml+1.93ml)/5ml
52 | Page
15 Rezulin 500 Tablet Pioglitazone + Metformin 15 mg + 500 mg
16 Rezulin 850 Tablet Pioglitazone + Metformin 15 mg + 850 mg
17 Secrin 1 tablet Glimepiride 1 mg
18 Secrin 2 tablet Glimepiride 2 mg
19 Secrin 3 tablet Glimepiride 3 mg
20 Secrin 4 tablet Glimepiride 4 mg
21 Sensimet 1 tablet Rosiglitazone + Metformin 1 mg + 500 mg
22 Sensimet 2 tablet Rosiglitazone + Metformin 2 mg + 500 mg
23 Sensimet 4 tablet Rosiglitazone + Metformin 4 mg + 500 mg
24 Sensimet 1 DS tablet Rosiglitazone + Metformin 2 mg + 1000 mg
25 Sensimet 2 DS tablet Rosiglitazone + Metformin 4 mg + 1000 mg
26 Sensulin 2 tablet Rosiglitazone 2 mg
27 Sensulin 4 tablet Rosiglitazone 4 mg
28 Tos 15 Tablet Pioglitazone 15 mg
29 Tos 30 Tablet Pioglitazone 30 mg
30 Zitrol XR 2.5 Glipizide 2.5 mg
31 Zitrol XR 5 Glipizide 5 mg
32 Zirol XR 10 Glipizide 10 mg
33 Tosirin 30/2 tablet Pioglitazone INN+Glimepiride USP 30 mg+2 mg
34 Tosirin 30/4 tablet Pioglitazone INN+Glimepiride USP 30 mg+4 mg
53 | Page
6 Iventi Eye Drops Moxifloxacin 0.50%
7 Mexlo Eye Drops Lomefloxacin 3 mg / ml
8 Nacromin 2% Eye Drops Sodium Cromoglycate 20 mg / ml
9 Locular 0.2% Eye Drops Brimonidine Tartrate 0.20%
10 SQ-Mycetin Eye / Ear Drops Chloramphenicol 5mg/ml
11 Temlo 0.25% Eye Drops Timolol Maleate 2.5 mg/ml
12 Temlo 0.50% Eye Drops Timolol Maleate 5 mg/ml
54 | Page
(100 mcg + 20 mcg) /
25 Sulprex Inhaler Salbutamol + Ipratropium
puff
26 Ticamet 50 Inhaler Salmeterol + Fluticasone (25 mcg+ 50 mcg) / puff
27 Ticamet 125 Inhaler Salmeterol + Fluticasone (25 mcg+125 mcg) / puff
28 Ticamet 250 Inhaler Salmeterol + Fluticasone (25 mcg+250 mcg) / puff
29 Ticamet 100 Cozycap Salmeterol + Fluticasone 50mcg+100 mcg
30 Ticamet 250 Cozycap Salmeterol + Fluticasone 50mcg+250 mcg
31 Optiven 10 tablet Bambuterol 10 mg
32 Optiven 20 tablet Bambuterol 20 mg
33 Optiven oral solution Bambuterol HCl 5mg/5ml
55 | Page
Market segment: ANTICHOLINERGIC
1 Ucol 2 tablet Tolterodine Tartrate 2mg
Cinchocaine + Hydrocortisone + 5 mg + 5 mg + 10 mg +
2 Erian Ointment
Framycetin + Esculin 10mg
56 | Page